Home/Pipeline/Undisclosed Neurology Programs

Undisclosed Neurology Programs

Neurological Disorders

DiscoveryActive

Key Facts

Indication

Neurological Disorders

Phase

Discovery

Status

Active

Company

BridGene Biosciences

About BridGene Biosciences

BridGene Biosciences is an early-stage, platform-focused biotech leveraging its innovative IMTAC™ chemoproteomics technology to tackle undruggable disease targets. The company's approach allows for the systematic screening of small molecules against the entire proteome, identifying novel binding sites and chemical starting points for drug development. Its initial pipeline is concentrated in oncology, with programs targeting transcription factors and other difficult proteins. As a private company, BridGene's success hinges on validating its platform through internal pipeline advancement and strategic partnerships.

View full company profile

Therapeutic Areas

Oncology Neurology Immunology

Other Neurological Disorders Drugs

Drug	Company	Phase	Status
Biomarker Development Program	NeuroVision Imaging	Research	Active
GlyT2 Inhibitor Program	Micar Innovation	Discovery	Active
Biomarker Discovery & Validation Services	NeuroDex	Service	Active
Clinical Trial Biomarker Support	NeuroDex	Service	Active
CNS-Targeting Capsids	rAAVen Therapeutics	Pre-clinical	Active
IVL-002	InVirtuoLabs	Discovery	Active
IVL-003	InVirtuoLabs	Discovery	Active
Neurology Diagnostics Program	Aptus Biosciences	Discovery	Active
GM1 Ganglioside-based Therapies	TRB Chemedica International	Commercial / Development	Active
iPSC Platform Programs	Evotec	Preclinical Research	Active
ExacTcell Platform	Tevogen Bio	Discovery/Preclinical	Research